SEC and FDA sign three-year info-sharing pact to boost market integrity and public-health oversight

The U.S. Securities and Exchange Commission and the Food and Drug Administration have entered into a three-year memorandum of understanding to expand cooperation and share information.

The MOU is designed to help both agencies protect public health and maintain the integrity of financial markets by allowing the SEC to access FDA-related disclosures from public companies, especially those involved in clinical trials and drug approvals.

Officials said the partnership will improve enforcement of insider-trading rules and ensure that false or misleading FDA information does not distort market prices, a move welcomed by investors and biotech firms.